Abstract: An interconnect structure and methods of forming the same are described. In some embodiments, the structure includes a first dielectric layer disposed over a substrate, a second dielectric layer disposed over the first dielectric layer, and a first conductive feature disposed in the second dielectric layer. The first conductive feature has a first top critical dimension and a first height. The structure further includes a second conductive feature disposed in the first and second dielectric layers. The second conductive feature has a second top critical dimension substantially greater than the first top critical dimension and a second height substantially greater than the first height.

Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.

Abstract: A connecting structure includes a first dielectric layer, a first connecting via in the first dielectric layer, a second connecting via in the first dielectric layer, and an isolation between the first connecting via and the second connecting via. The isolation separates the first and second connecting vias from each other. The first connecting via, the isolation and the second connecting via are line symmetrical about a central line perpendicular to a top surface of the first dielectric layer.

Abstract: The present disclosure provides a routing structure. The routing structure includes a substrate having a boundary and a first conductive trace configured to be coupled to a first conductive pad disposed within the boundary of the substrate. The first conductive trace is inclined with respect to the boundary of the substrate.

Abstract: An organic light emitting diode display according to an exemplary embodiment includes: a substrate; a first buffer layer on the substrate; a first semiconductor layer on the first buffer layer; a first gate insulating layer on the first semiconductor layer; a first gate electrode and a blocking layer on the first gate insulating layer; a second buffer layer on the first gate electrode; a second semiconductor layer on the second buffer layer; a second gate insulating layer on the second semiconductor layer; and a second gate electrode on the second gate insulating layer.

Abstract: A semiconductor structure includes several semiconductor stacks over a substrate, and each of the semiconductor stacks extends in a first direction, wherein adjacent semiconductor stacks are spaced apart from each other in a second direction, which is different from the first direction. Each of the semiconductor stacks includes channel layers above the substrate and a gate structure across the channel layers. The channel layers are spaced apart from each other in the third direction. The gate structure includes gate dielectric layers around the respective channel layers, and a gate electrode along sidewalls of the gate dielectric layers and a top surface of the uppermost gate dielectric layer. The space in the third direction between the two lowermost channel layers is greater than the space in the third direction between the two uppermost channel layers in the same semiconductor stack.

Abstract: A semiconductor device is provided. The semiconductor device includes a semiconductor fin over a substrate, and a gate structure along sidewalls and the top surface of the semiconductor fin. The gate structure covers the first portion of the semiconductor fin. The semiconductor device also includes a source/drain feature adjacent to the gate structure. The semiconductor device further includes a source/drain contact connected to the source/drain feature. The source/drain contact extends downwards to a position that is lower than the top surface of the first portion of the semiconductor fin.

Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fe receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

Abstract: A hydrophobic admixture, for cementitious materials such as cement paste, mortar, and concrete, includes solid polymer particles with a coating of hydrophobic agent and surfactant. The solid polymer particles adhere to exterior surfaces of hydrated cement particles in the cement matrix. The solid polymer particles deliver the hydrophobic agent into the cement matrix which is hydrophilic. The hydrophobic agents are distributed uniformly throughout the cement matrix. The solid polymer particles can be crumb rubber particles derived from waste rubber tires, recycled plastics and similar solid materials. The hydrophobic liquid agent is derived from waste lubricant oil, spent motor oil, base oil, esters of fatty acids, vegetable oil and the like. Fine particles such as activated carbon, silica fume and spent catalyst can be employed to fill the large pores or cracks that develop in the cementitious matrix. The cured cementitious materials exhibit high contact angles and high compressive strengths.

Abstract: A hydrophobic admixture, for cementitious materials such as cement paste, mortar, and concrete, includes solid polymer particles with a coating of hydrophobic agent and surfactant. The solid polymer particles adhere to exterior surfaces of hydrated cement particles in the cement matrix. The solid polymer particles deliver the hydrophobic agent into the cement matrix which is hydrophilic. The hydrophobic agents are distributed uniformly throughout the cement matrix. The solid polymer particles can be crumb rubber particles derived from waste rubber tires, recycled plastics and similar solid materials. The hydrophobic liquid agent is derived from waste lubricant oil, spent motor oil, base oil, esters of fatty acids, vegetable oil and the like. Fine particles such as activated carbon, silica fume and spent catalyst can be employed to fill the large pores or cracks that develop in the cementitious matrix. The cured cementitious materials exhibit high contact angles and high compressive strengths.

Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Abstract: Described herein are methods for treating or preventing leukemias with NK-92 cells. In particular, provided are methods of treating or preventing leukemias by administering to a patient one or more doses of NK-92 cells for killing remnant (also referred to as residual) leukemia cells and/or leukemia stem cells. In various embodiments, NK-92 cells are administered to a patient to treat and/or prevent leukemia that is refractory or resistant, or has relapsed in a patient who is recovering from treatment for leukemia under conventional therapies.

Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.